Copenhagen-based biopharmaceutical company Ascendis Pharma A/S said its board of directors has authorized a share repurchase program of up to $400 million in the company's ordinary shares.
The company, listed on Nasdaq under the ticker ASND, said purchases may be made from time to time through open-market transactions, privately negotiated transactions, block trades, accelerated share repurchase transactions and 10b5-1 trading plans. The timing and size of repurchases will depend on market conditions, the share price and other factors.
The program does not require Ascendis Pharma to repurchase any specific number of shares and may be modified, suspended or terminated at any time without prior notice.
Ascendis Pharma focuses on applying its TransCon technology platform to develop therapies and operates facilities in Europe and the United States.
